

**FOR GENERAL RELEASE TO THE PUBLIC
March 13, 2020**

ANNOUNCEMENT REGARDING FINANCIAL GUIDANCE

In the January-February period of 2020, while both our domestic (20%) and foreign medical tourism (26%) revenue grew above our expectations, total hospital revenue increased by 21%. Although there was a slight decline in our foreign medical tourism revenues due to travel restrictions originating from COVID-19 in March, it is observed that strong domestic revenue growth compensates this weakness.

In addition, SSI price list was updated on March 3 to be effective after March 11. The new SSI prices, which came into effect in March, are expected to support domestic hospital revenue positively and compensate for losses that may occur in foreign medical tourism revenue. Our annual financial guidance announced on March 5, 2020 does not include the effect of updated SSI prices. In this context, we maintain our expectation of 18% revenue and 25% EBITDA growth in 2020.

We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.

ENQUIRIES

Dr. Deniz Can Yücel
Head of Strategy and Investor Relations
T +90 212 227 5555 (Ext: 1148)
E deniz.yucel@mlpcare.com